← Leaderboards
Kylene Kehn-Hall
George Mason University
$1,766,709
Attributed
$4,440,720
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $764.3K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,440,720 · 3
By mechanism
R01$3,558,248 · 1
R21$452,769 · 1
R15$429,703 · 1
Top collaborators
- Dmitri Konstantinovich Klimov5 shared
- Mikell Paige5 shared
- Jennifer E. Golden1 shared
- Colleen B Jonsson1 shared
Most similar at George Mason University
Same institution · by research overlap
- Farhang Alem$15,483,816
- Dmitri Konstantinovich Klimov$2,227,833
- Aarthi Narayanan$456,000
Others in their field
Top investigators on “Virus Diseases”
- Barton F Haynes · Duke University$305,832,186
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Lawrence Corey · Fred Hutchinson Cancer Center$271,990,515
- Richard Webby · St. Jude Children'S Research Hospital$264,105,723
- David Heimbrook · Leidos Biomedical Research, Inc.$262,417,885
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$252,117,999
Research focus
Virus DiseasesBehavioralNovel TherapeuticsViralCategory B PathogenSeizuresMemory LossNeuronsPreventVenezuelan Equine Encephalitis VirusDesignVirus ReplicationCessation Of LifeSmall MoleculeAcuteInflammationMouse ModelNational Institute Of Allergy And Infectious DiseaseComplexCellsAnimalsCell NucleusAlpha KaryopherinsChemical Structure
Grant awards (7)
Impact of BDGR-49 treatment on VEEV induced neurological sequelae$452,769
R21 · FY2025 · AI · contact PI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$708,202
R01 · FY2024 · AI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$679,799
R01 · FY2023 · AI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$687,849
R01 · FY2022 · AI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$718,061
R01 · FY2021 · AI
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection$764,337
R01 · FY2020 · AI
Induction of DNA Damage Signaling Cascade upon RVFV Infection$429,703
R15 · FY2013 · AI · contact PI